Trial Profile
The Safety and Efficacy of Macitentan for Treatment of Pulmonary Hypertension in Sickle Cell Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Macitentan (Primary)
- Indications Pulmonary hypertension
- Focus Adverse reactions
- Acronyms MENSCH
- 13 Nov 2020 Status has been changed to discontinued because because study is unable to enroll IRB approved sample of participants.
- 07 Feb 2020 Status changed from recruiting to completed.
- 15 Jan 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.